A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians

R. D. Burt, T. L. Vaughan, B. Nisperos, M. Swanson, M. Berwick

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Analyzing data from Caucasians participating in a multicentered population-based case-control study of nasopharyngeal carcinoma and HLA type in the US, we found persons with the A2 antigen to have a significantly lower risk than those with other antigens at the A locus [odds ratio (OR), 0.46; 95% confidence interval (CI), 0.21-0.96]. The protective association was stronger among presumptive homozygotes for A2. Similar results were obtained when cases were compared with US Caucasians typed either as part of the Collaborative Transplant Study, or by the 9th International Histocompatibility Workshop. These results are supported by a statistical summary of odds ratios for A2 from a number of previous studies in non- Chinese (summary OR, 0.69; 95% CI, 0.54-0.88). The odds ratio for patients with squamous-cell carcinomas was 0.56; among 7 patients with undifferentiated tumors the OR was 0.14. Results from in vitro studies of immune response to Epstein-Barr virus have found that the HLA-A2 antigen efficiently presents the EBV gene product LMP-2, which has been detected in NPC tumor cells. This offers a rationale for the observed protective association between the HLA-A2 antigen and nasopharyngeal carcinoma.

Original languageEnglish (US)
Pages (from-to)465-467
Number of pages3
JournalInternational Journal of Cancer
Volume56
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

HLA-A2 Antigen
Odds Ratio
varespladib methyl
Human Herpesvirus 4
Confidence Intervals
Antigens
Histocompatibility
Homozygote
Case-Control Studies
Squamous Cell Carcinoma
Neoplasms
Nasopharyngeal carcinoma
Transplants
Education
Population
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Burt, R. D., Vaughan, T. L., Nisperos, B., Swanson, M., & Berwick, M. (1994). A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. International Journal of Cancer, 56(4), 465-467.

A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. / Burt, R. D.; Vaughan, T. L.; Nisperos, B.; Swanson, M.; Berwick, M.

In: International Journal of Cancer, Vol. 56, No. 4, 1994, p. 465-467.

Research output: Contribution to journalArticle

Burt, RD, Vaughan, TL, Nisperos, B, Swanson, M & Berwick, M 1994, 'A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians', International Journal of Cancer, vol. 56, no. 4, pp. 465-467.
Burt, R. D. ; Vaughan, T. L. ; Nisperos, B. ; Swanson, M. ; Berwick, M. / A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. In: International Journal of Cancer. 1994 ; Vol. 56, No. 4. pp. 465-467.
@article{d1db1071a9464e1d9fcd90f10d959a11,
title = "A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians",
abstract = "Analyzing data from Caucasians participating in a multicentered population-based case-control study of nasopharyngeal carcinoma and HLA type in the US, we found persons with the A2 antigen to have a significantly lower risk than those with other antigens at the A locus [odds ratio (OR), 0.46; 95{\%} confidence interval (CI), 0.21-0.96]. The protective association was stronger among presumptive homozygotes for A2. Similar results were obtained when cases were compared with US Caucasians typed either as part of the Collaborative Transplant Study, or by the 9th International Histocompatibility Workshop. These results are supported by a statistical summary of odds ratios for A2 from a number of previous studies in non- Chinese (summary OR, 0.69; 95{\%} CI, 0.54-0.88). The odds ratio for patients with squamous-cell carcinomas was 0.56; among 7 patients with undifferentiated tumors the OR was 0.14. Results from in vitro studies of immune response to Epstein-Barr virus have found that the HLA-A2 antigen efficiently presents the EBV gene product LMP-2, which has been detected in NPC tumor cells. This offers a rationale for the observed protective association between the HLA-A2 antigen and nasopharyngeal carcinoma.",
author = "Burt, {R. D.} and Vaughan, {T. L.} and B. Nisperos and M. Swanson and M. Berwick",
year = "1994",
language = "English (US)",
volume = "56",
pages = "465--467",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians

AU - Burt, R. D.

AU - Vaughan, T. L.

AU - Nisperos, B.

AU - Swanson, M.

AU - Berwick, M.

PY - 1994

Y1 - 1994

N2 - Analyzing data from Caucasians participating in a multicentered population-based case-control study of nasopharyngeal carcinoma and HLA type in the US, we found persons with the A2 antigen to have a significantly lower risk than those with other antigens at the A locus [odds ratio (OR), 0.46; 95% confidence interval (CI), 0.21-0.96]. The protective association was stronger among presumptive homozygotes for A2. Similar results were obtained when cases were compared with US Caucasians typed either as part of the Collaborative Transplant Study, or by the 9th International Histocompatibility Workshop. These results are supported by a statistical summary of odds ratios for A2 from a number of previous studies in non- Chinese (summary OR, 0.69; 95% CI, 0.54-0.88). The odds ratio for patients with squamous-cell carcinomas was 0.56; among 7 patients with undifferentiated tumors the OR was 0.14. Results from in vitro studies of immune response to Epstein-Barr virus have found that the HLA-A2 antigen efficiently presents the EBV gene product LMP-2, which has been detected in NPC tumor cells. This offers a rationale for the observed protective association between the HLA-A2 antigen and nasopharyngeal carcinoma.

AB - Analyzing data from Caucasians participating in a multicentered population-based case-control study of nasopharyngeal carcinoma and HLA type in the US, we found persons with the A2 antigen to have a significantly lower risk than those with other antigens at the A locus [odds ratio (OR), 0.46; 95% confidence interval (CI), 0.21-0.96]. The protective association was stronger among presumptive homozygotes for A2. Similar results were obtained when cases were compared with US Caucasians typed either as part of the Collaborative Transplant Study, or by the 9th International Histocompatibility Workshop. These results are supported by a statistical summary of odds ratios for A2 from a number of previous studies in non- Chinese (summary OR, 0.69; 95% CI, 0.54-0.88). The odds ratio for patients with squamous-cell carcinomas was 0.56; among 7 patients with undifferentiated tumors the OR was 0.14. Results from in vitro studies of immune response to Epstein-Barr virus have found that the HLA-A2 antigen efficiently presents the EBV gene product LMP-2, which has been detected in NPC tumor cells. This offers a rationale for the observed protective association between the HLA-A2 antigen and nasopharyngeal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0028328477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028328477&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 465

EP - 467

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -